In-vitro and in-vivo evaluation of sustained-release buprenorphine using in-situ forming lipid-liquid crystal gels

Aims: Sustained-release systems reduce the incidence of drug side effects and the need for frequent drug con-sumption, thus increasing patient compliance with treatment. In this study, we aimed to produce sustained -release buprenorphine (BP) using lipid-liquid crystal gels.Main methods: The three experimental groups in this study included: group I: lipid-liquid crystal formulation 5 (F5) containing BP, group II: BP-free F5, group III: BP solution in NMP, and group IV: control (no treatment). The formulations were injected subcutaneously into the rabbits' back neck.Key findings: The results showed that the time required to reach the drug's maximum concentration (Tmax) was longer in group I than in group III. The maximum BP concentration (Cmax) and the constants of the drug removal rate and drug absorption rate (Ka) were significantly higher in group III compared to group I. The half-life (t1/2) of the drug in blood circulation was significantly longer in group I than in group III. Histopathological analysis revealed no histological abnormalities in the skin and heart in group I (BP-containing F5); however, mild hy-peremia was observed in interstitial vessels in group III (BP-containing NMP). The kidney and liver tissues showed normal structure in the control group, as well as groups I and II. However, in the group receiving BP -containing NMP, significant congestion, tissue damage, necrosis, and fibrosis were observed in the kidney and liver.Significance: The results showed that the lipid-liquid crystal system can be used to design slow-release platforms for BP, minimizing the side effects associated with the use of its conventional forms.

Automated summary

The study aimed to produce sustained-release buprenorphine using lipid-liquid crystal gels. The results showed that the lipid-liquid crystal system can be used to design slow-release platforms for buprenorphine, minimizing its side effects.